Eagle Pharmaceuticals, Inc. Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Eagle Pharmaceuticals (EGRX) PT Raised to $120 at Piper Jaffray
August 12, 2015 8:28 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and lifted his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $120.00 (from $119.00) following the company's Q2 update.
commented, "This morning, Eagle reported net results per share of ($0.53) on revenues of $6M. Management provided... More
Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 4c
August 11, 2015 7:48 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $6 million versus the consensus estimate of $4.7 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More